These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 29902299)

  • 1. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
    Powles RL; Redmond D; Sotiriou C; Loi S; Fumagalli D; Nuciforo P; Harbeck N; de Azambuja E; Sarp S; Di Cosimo S; Huober J; Baselga J; Piccart-Gebhart M; Elemento O; Pusztai L; Hatzis C
    JAMA Oncol; 2018 Nov; 4(11):e181564. PubMed ID: 29902299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
    Fernandez-Martinez A; Rediti M; Tang G; Pascual T; Hoadley KA; Venet D; Rashid NU; Spears PA; Islam MN; El-Abed S; Bliss J; Lambertini M; Di Cosimo S; Huobe J; Goerlitz D; Hu R; Lucas PC; Swain SM; Sotiriou C; Perou CM; Carey LA
    JAMA Oncol; 2024 May; 10(5):603-611. PubMed ID: 38546612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
    Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
    ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
    Fernandez-Martinez A; Pascual T; Singh B; Nuciforo P; Rashid NU; Ballman KV; Campbell JD; Hoadley KA; Spears PA; Pare L; Brasó-Maristany F; Chic N; Krop I; Partridge A; Cortés J; Llombart-Cussac A; Prat A; Perou CM; Carey LA
    JAMA Oncol; 2023 Apr; 9(4):490-499. PubMed ID: 36602784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
    Huober J; Holmes E; Baselga J; de Azambuja E; Untch M; Fumagalli D; Sarp S; Lang I; Smith I; Boyle F; Xu B; Lecocq C; Wildiers H; Jouannaud C; Hackman J; Dasappa L; Ciruelos E; Toral Pena JC; Adamchuk H; Hickish T; de la Pena L; Jackisch C; Gelber RD; Piccart-Gebhart M; Di Cosimo S
    Eur J Cancer; 2019 Sep; 118():169-177. PubMed ID: 31377477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
    Fumagalli D; Venet D; Ignatiadis M; Azim HA; Maetens M; Rothé F; Salgado R; Bradbury I; Pusztai L; Harbeck N; Gomez H; Chang TW; Coccia-Portugal MA; Di Cosimo S; de Azambuja E; de la Peña L; Nuciforo P; Brase JC; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C
    JAMA Oncol; 2017 Feb; 3(2):227-234. PubMed ID: 27684533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.
    Di Cosimo S; Triulzi T; Pizzamiglio S; De Cecco L; de Azambuja E; Fumagalli D; Putzai L; Harbeck N; Izquierdo M; Peña L; Daidone MG; Huober J; Gori S; Cinieri S; Torri V; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Tagliabue E
    Eur J Cancer; 2019 Sep; 118():1-9. PubMed ID: 31284184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
    Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
    Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
    Carey LA; Berry DA; Cirrincione CT; Barry WT; Pitcher BN; Harris LN; Ollila DW; Krop IE; Henry NL; Weckstein DJ; Anders CK; Singh B; Hoadley KA; Iglesia M; Cheang MC; Perou CM; Winer EP; Hudis CA
    J Clin Oncol; 2016 Feb; 34(6):542-9. PubMed ID: 26527775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
    Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
    J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
    Hurvitz SA; Caswell-Jin JL; McNamara KL; Zoeller JJ; Bean GR; Dichmann R; Perez A; Patel R; Zehngebot L; Allen H; Bosserman L; DiCarlo B; Kennedy A; Giuliano A; Calfa C; Molthrop D; Mani A; Chen HW; Dering J; Adams B; Kotler E; Press MF; Brugge JS; Curtis C; Slamon DJ
    Nat Commun; 2020 Nov; 11(1):5824. PubMed ID: 33203854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
    Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
    Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
    Fernandez-Martinez A; Krop IE; Hillman DW; Polley MY; Parker JS; Huebner L; Hoadley KA; Shepherd J; Tolaney S; Henry NL; Dang C; Harris L; Berry D; Hahn O; Hudis C; Winer E; Partridge A; Perou CM; Carey LA
    J Clin Oncol; 2020 Dec; 38(35):4184-4193. PubMed ID: 33095682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
    Lambertini M; Martel S; Campbell C; Guillaume S; Hilbers FS; Schuehly U; Korde L; Azim HA; Di Cosimo S; Tenglin RC; Huober J; Baselga J; Moreno-Aspitia A; Piccart-Gebhart M; Gelber RD; de Azambuja E; Ignatiadis M
    Cancer; 2019 Jan; 125(2):307-316. PubMed ID: 30335191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
    Nuciforo P; Townend J; Piccart MJ; Fielding S; Gkolfi P; El-Abed S; de Azambuja E; Werutsky G; Bliss J; Moebus V; Colleoni M; Aspitia AM; Gomez H; Gombos A; Coccia-Portugal MA; Tseng LM; Kunz G; Lerzo G; Sohn J; Semiglazov V; Saura C; Kroep J; Ferro A; Cameron D; Gelber R; Huober J; Di Cosimo S
    Eur J Cancer; 2023 Mar; 181():92-101. PubMed ID: 36641898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.